Corcept Therapeutics Incorporated (CORT)vsRoyalty Pharma Plc (RPRX)
CORT
Corcept Therapeutics Incorporated
$72.62
-3.03%
HEALTHCARE · Cap: $8.90B
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 217% more annual revenue ($2.44B vs $769.10M). RPRX leads profitability with a 33.9% profit margin vs 6.2%. CORT appears more attractively valued with a PEG of 0.81. RPRX earns a higher WallStSmart Score of 65/100 (C+).
CORT
Hold37
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CORT.
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Trading at 12.2x book value
4.9% revenue growth
ROE of 7.5% — below average capital efficiency
6.2% margin — thin
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CORT
The strongest argument for CORT centers on Debt/Equity, Altman Z-Score, PEG Ratio. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : CORT
The primary concerns for CORT are Price/Book, Revenue Growth, Return on Equity. A P/E of 236.9x leaves little room for execution misses.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
CORT profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
CORT carries more volatility with a beta of 0.50 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 37/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Corcept Therapeutics Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?